Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum

tolvaptan

  • You have accessRestricted Access
    Long-Term Safety of Tolvaptan in ADPKD
    Dipal M. Patel and Neera K. Dahl
    CJASN January 2021, 16 (1) 3-5; DOI: https://doi.org/10.2215/CJN.17981120
    Add to Selected Citations
  • Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Open Access
    Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
    Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Jennifer Lee, Molly E. Hoke, Alvin Estilo and Olga Sergeyeva
    CJASN January 2021, 16 (1) 48-58; DOI: https://doi.org/10.2215/CJN.10250620
    Add to Selected Citations
  • Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
    You have accessRestricted Access
    Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
    Matteo Bargagli, Nasser A. Dhayat, Manuel Anderegg, Mariam Semmo, Uyen Huynh-Do, Bruno Vogt, Pietro Manuel Ferraro and Daniel G. Fuster
    CJASN July 2020, 15 (7) 1007-1014; DOI: https://doi.org/10.2215/CJN.13861119
    Add to Selected Citations
  • You have accessRestricted Access
    ADPKD, Tolvaptan, and Nephrolithiasis Risk
    Ewout J. Hoorn and Robert Zietse
    CJASN July 2020, 15 (7) 923-925; DOI: https://doi.org/10.2215/CJN.07610520
    Add to Selected Citations
  • A <em>Post Hoc</em> Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials
    You have accessRestricted Access
    A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials
    Susan E. Shoaf, John Ouyang, Olga Sergeyeva, Alvin Estilo, Hui Li and Deborah Leung
    CJASN May 2020, 15 (5) 643-650; DOI: https://doi.org/10.2215/CJN.08170719
    Add to Selected Citations
  • You have accessRestricted Access
    Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease
    Kristen L. Nowak and Katharina Hopp
    CJASN April 2020, 15 (4) 577-584; DOI: https://doi.org/10.2215/CJN.13291019
    Add to Selected Citations
  • Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    You have accessRestricted Access
    Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Marie E. Edwards, Fouad T. Chebib, Maria V. Irazabal, Troy G. Ofstie, Lisa A. Bungum, Andrew J. Metzger, Sarah R. Senum, Marie C. Hogan, Ziad M. El-Zoghby, Timothy L. Kline, Peter C. Harris, Frank S. Czerwiec and Vicente E. Torres
    CJASN August 2018, 13 (8) 1153-1161; DOI: https://doi.org/10.2215/CJN.01520218
    Add to Selected Citations
  • Open Access
    Burden of Proof for Tolvaptan in ADPKD
    Reem A. Mustafa and Alan S.L. Yu
    CJASN July 2018, 13 (7) 1107-1109; DOI: https://doi.org/10.2215/CJN.00190118
    Add to Selected Citations
  • You have accessRestricted Access
    Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
    Vicente E. Torres, Eiji Higashihara, Olivier Devuyst, Arlene B. Chapman, Ronald T. Gansevoort, Jared J. Grantham, Ronald D. Perrone, John Ouyang, Jaime D. Blais and Frank S. Czerwiec
    CJASN May 2016, 11 (5) 803-811; DOI: https://doi.org/10.2215/CJN.06300615
    Add to Selected Citations
  • You have accessRestricted Access
    Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management
    Helbert Rondon-Berrios and Tomas Berl
    CJASN December 2015, 10 (12) 2268-2278; DOI: https://doi.org/10.2215/CJN.00170115
    Add to Selected Citations

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire